Becton Dickinson Debt to Equity Ratio 2010-2024 | BDX
Current and historical debt to equity ratio values for Becton Dickinson (BDX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Becton Dickinson debt/equity for the three months ending September 30, 2024 was 0.69.
| Becton Dickinson Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-09-30 |
$31.40B |
$25.89B |
1.21 |
| 2024-06-30 |
$29.71B |
$25.87B |
1.15 |
| 2024-03-31 |
$28.51B |
$25.65B |
1.11 |
| 2023-12-31 |
$26.94B |
$25.33B |
1.06 |
| 2023-09-30 |
$26.98B |
$25.80B |
1.05 |
| 2023-06-30 |
$27.08B |
$25.94B |
1.04 |
| 2023-03-31 |
$28.71B |
$25.69B |
1.12 |
| 2022-12-31 |
$27.66B |
$25.47B |
1.09 |
| 2022-09-30 |
$27.65B |
$25.28B |
1.09 |
| 2022-06-30 |
$27.71B |
$25.49B |
1.09 |
| 2022-03-31 |
$30.26B |
$24.53B |
1.23 |
| 2021-12-31 |
$29.20B |
$24.16B |
1.21 |
| 2021-09-30 |
$30.19B |
$23.68B |
1.28 |
| 2021-06-30 |
$30.20B |
$24.14B |
1.25 |
| 2021-03-31 |
$30.09B |
$24.83B |
1.21 |
| 2020-12-31 |
$30.09B |
$24.66B |
1.22 |
| 2020-09-30 |
$30.25B |
$23.77B |
1.27 |
| 2020-06-30 |
$29.94B |
$24.02B |
1.25 |
| 2020-03-31 |
$32.57B |
$20.95B |
1.55 |
| 2019-12-31 |
$30.75B |
$21.20B |
1.45 |
| 2019-09-30 |
$30.68B |
$21.08B |
1.46 |
| 2019-06-30 |
$30.74B |
$21.50B |
1.43 |
| 2019-03-31 |
$31.29B |
$21.31B |
1.47 |
| 2018-12-31 |
$31.53B |
$21.40B |
1.47 |
| 2018-09-30 |
$32.91B |
$20.99B |
1.57 |
| 2018-06-30 |
$32.62B |
$21.36B |
1.53 |
| 2018-03-31 |
$33.42B |
$21.15B |
1.58 |
| 2017-12-31 |
$34.12B |
$21.25B |
1.61 |
| 2017-09-30 |
$24.79B |
$12.95B |
1.91 |
| 2017-06-30 |
$24.58B |
$12.59B |
1.95 |
| 2017-03-31 |
$16.16B |
$7.96B |
2.03 |
| 2016-12-31 |
$16.74B |
$7.58B |
2.21 |
| 2016-09-30 |
$17.95B |
$7.63B |
2.35 |
| 2016-06-30 |
$17.98B |
$8.03B |
2.24 |
| 2016-03-31 |
$18.57B |
$7.67B |
2.42 |
| 2015-12-31 |
$18.82B |
$7.22B |
2.61 |
| 2015-09-30 |
$19.31B |
$7.16B |
2.70 |
| 2015-06-30 |
$19.83B |
$7.25B |
2.73 |
| 2015-03-31 |
$21.13B |
$7.16B |
2.95 |
| 2014-12-31 |
$13.44B |
$5.07B |
2.65 |
| 2014-09-30 |
$7.39B |
$5.05B |
1.46 |
| 2014-06-30 |
$7.00B |
$5.38B |
1.30 |
| 2014-03-31 |
$6.94B |
$5.32B |
1.31 |
| 2013-12-31 |
$6.96B |
$5.08B |
1.37 |
| 2013-09-30 |
$7.11B |
$5.04B |
1.41 |
| 2013-06-30 |
$6.87B |
$4.72B |
1.46 |
| 2013-03-31 |
$7.04B |
$4.59B |
1.53 |
| 2012-12-31 |
$7.16B |
$4.47B |
1.60 |
| 2012-09-30 |
$7.23B |
$4.14B |
1.75 |
| 2012-06-30 |
$6.79B |
$4.24B |
1.60 |
| 2012-03-31 |
$6.72B |
$4.48B |
1.50 |
| 2011-12-31 |
$6.69B |
$4.73B |
1.41 |
| 2011-09-30 |
$5.60B |
$4.83B |
1.16 |
| 2011-06-30 |
$5.32B |
$5.30B |
1.01 |
| 2011-03-31 |
$5.25B |
$5.10B |
1.03 |
| 2010-12-31 |
$5.19B |
$4.88B |
1.07 |
| 2010-09-30 |
$4.22B |
$5.44B |
0.78 |
| 2010-06-30 |
$3.88B |
$5.15B |
0.75 |
| 2010-03-31 |
$3.79B |
$5.15B |
0.74 |
| 2009-12-31 |
$3.83B |
$5.26B |
0.73 |
| 2009-09-30 |
$4.16B |
$5.14B |
0.81 |
| 2009-06-30 |
$3.64B |
$5.21B |
0.70 |
| 2009-03-31 |
$2.77B |
$4.80B |
0.58 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$64.714B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
